SCHEDULE: Commodore Capital Exits Cardiff Oncology Stake

Commodore Capital LP and Commodore Capital Master LP report zero beneficial ownership in Cardiff Oncology, Inc., indicating a full divestment of their previous stake.

Summary

• Commodore Capital LP and Commodore Capital Master LP filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Cardiff Oncology, Inc.
• The filing indicates that both Commodore Capital LP and Commodore Capital Master LP now beneficially own 0.00 shares of Cardiff Oncology, Inc. Common Stock.
• This represents 0.0% of the class of securities.
• The event date requiring this filing, which signifies the change in ownership, was June 30, 2025.
• The filing confirms a complete divestment of their previously held position in Cardiff Oncology, Inc.

Sentiment

Score: 3

Explanation: The complete divestment by a beneficial owner, Commodore Capital, is generally a negative signal for the issuer's stock, indicating a lack of confidence or a strategic exit by a significant investor.

Negatives

• Commodore Capital LP and Commodore Capital Master LP have fully divested their beneficial ownership in Cardiff Oncology, Inc.
• The reporting persons now hold 0.0% of the common stock, down from a previously reportable stake (implied by the initial Schedule 13G filing requirement).

Future Outlook

NA

Industry Context

This filing indicates a significant investor, Commodore Capital, has exited its position in Cardiff Oncology. Such divestments can sometimes signal a change in investor sentiment or strategy regarding the company or the broader biotechnology sector, though the filing itself does not provide reasons.

Stakeholder Impact

• Shareholders may view the divestment by a significant investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The complete divestment by Commodore Capital, a previously significant beneficial owner, signals a lack of confidence or a strategic exit. This action by an institutional investor often precedes or accompanies negative price movements, suggesting a 'sell' recommendation for investors holding the stock or considering an investment, as it indicates a significant institutional player no longer sees value in holding the shares.

Keywords

Cardiff Oncology, Commodore Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Biotechnology, Investment Management